191 related articles for article (PubMed ID: 37047448)
1. Triple Negative Breast Cancer Preclinical Therapeutic Management by a Cationic Ruthenium-Based Nucleolipid Nanosystem.
Ferraro MG; Bocchetti M; Riccardi C; Trifuoggi M; Paduano L; Montesarchio D; Misso G; Santamaria R; Piccolo M; Irace C
Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047448
[TBL] [Abstract][Full Text] [Related]
2. Breast Cancer Chemotherapeutic Options: A General Overview on the Preclinical Validation of a Multi-Target Ruthenium(III) Complex Lodged in Nucleolipid Nanosystems.
Ferraro MG; Piccolo M; Misso G; Maione F; Montesarchio D; Caraglia M; Paduano L; Santamaria R; Irace C
Cells; 2020 Jun; 9(6):. PubMed ID: 32517101
[TBL] [Abstract][Full Text] [Related]
3. Exploring cellular uptake, accumulation and mechanism of action of a cationic Ru-based nanosystem in human preclinical models of breast cancer.
Piccolo M; Misso G; Ferraro MG; Riccardi C; Capuozzo A; Zarone MR; Maione F; Trifuoggi M; Stiuso P; D'Errico G; Caraglia M; Paduano L; Montesarchio D; Irace C; Santamaria R
Sci Rep; 2019 May; 9(1):7006. PubMed ID: 31065032
[TBL] [Abstract][Full Text] [Related]
4. Cellular responses of BRCA1-defective and triple-negative breast cancer cells and in vitro BRCA1 interactions induced by metallo-intercalator ruthenium(II) complexes containing chloro-substituted phenylazopyridine.
Nhukeaw T; Temboot P; Hansongnern K; Ratanaphan A
BMC Cancer; 2014 Feb; 14():73. PubMed ID: 24507701
[TBL] [Abstract][Full Text] [Related]
5. Safety and Efficacy Evaluation In Vivo of a Cationic Nucleolipid Nanosystem for the Nanodelivery of a Ruthenium(III) Complex with Superior Anticancer Bioactivity.
Piccolo M; Ferraro MG; Raucci F; Riccardi C; Saviano A; Russo Krauss I; Trifuoggi M; Caraglia M; Paduano L; Montesarchio D; Maione F; Misso G; Santamaria R; Irace C
Cancers (Basel); 2021 Oct; 13(20):. PubMed ID: 34680314
[TBL] [Abstract][Full Text] [Related]
6. BRCA1-Associated Triple-Negative Breast Cancer and Potential Treatment for Ruthenium-Based Compounds.
Hongthong K; Ratanaphan A
Curr Cancer Drug Targets; 2016; 16(7):606-17. PubMed ID: 26845433
[TBL] [Abstract][Full Text] [Related]
7. The trans-[Ru(PPh
Becceneri AB; Popolin CP; Plutin AM; Maistro EL; Castellano EE; Batista AA; Cominetti MR
J Inorg Biochem; 2018 Sep; 186():70-84. PubMed ID: 29857173
[TBL] [Abstract][Full Text] [Related]
8. Investigating the Interaction of an Anticancer Nucleolipidic Ru(III) Complex with Human Serum Proteins: A Spectroscopic Study.
Riccardi C; Campanella A; Montesarchio D; Del Vecchio P; Oliva R; Paduano L
Molecules; 2023 Mar; 28(6):. PubMed ID: 36985771
[TBL] [Abstract][Full Text] [Related]
9. The water soluble ruthenium(II) organometallic compound [Ru(p-cymene)(bis(3,5 dimethylpyrazol-1-yl)methane)Cl]Cl suppresses triple negative breast cancer growth by inhibiting tumor infiltration of regulatory T cells.
Montani M; Pazmay GVB; Hysi A; Lupidi G; Pettinari R; Gambini V; Tilio M; Marchetti F; Pettinari C; Ferraro S; Iezzi M; Marchini C; Amici A
Pharmacol Res; 2016 May; 107():282-290. PubMed ID: 27038531
[TBL] [Abstract][Full Text] [Related]
10. In Vivo Performance of a Ruthenium-cyclopentadienyl Compound in an Orthotopic Triple Negative Breast Cancer Model.
Mendes N; Tortosa F; Valente A; Marques F; Matos A; Morais TS; Tomaz AI; Gärtner F; Garcia MH
Anticancer Agents Med Chem; 2017; 17(1):126-136. PubMed ID: 27671310
[TBL] [Abstract][Full Text] [Related]
11. Cytotoxicity and anti-tumor effects of new ruthenium complexes on triple negative breast cancer cells.
Popolin CP; Reis JPB; Becceneri AB; Graminha AE; Almeida MAP; Corrêa RS; Colina-Vegas LA; Ellena J; Batista AA; Cominetti MR
PLoS One; 2017; 12(9):e0183275. PubMed ID: 28898246
[TBL] [Abstract][Full Text] [Related]
12. Half-sandwich Os(ii) and Ru(ii) bathophenanthroline complexes: anticancer drug candidates with unusual potency and a cellular activity profile in highly invasive triple-negative breast cancer cells.
Pracharova J; Novohradsky V; Kostrhunova H; Štarha P; Trávníček Z; Kasparkova J; Brabec V
Dalton Trans; 2018 Sep; 47(35):12197-12208. PubMed ID: 30112527
[TBL] [Abstract][Full Text] [Related]
13. Transport of the Ruthenium Complex [Ru(GA)(dppe)
Naves MA; Graminha AE; Vegas LC; Luna-Dulcey L; Honorato J; Menezes ACS; Batista AA; Cominetti MR
Mol Pharm; 2019 Mar; 16(3):1167-1183. PubMed ID: 30633527
[TBL] [Abstract][Full Text] [Related]
14. A new design for nucleolipid-based Ru(III) complexes as anticancer agents.
Montesarchio D; Mangiapia G; Vitiello G; Musumeci D; Irace C; Santamaria R; D'Errico G; Paduano L
Dalton Trans; 2013 Dec; 42(48):16697-708. PubMed ID: 24121739
[TBL] [Abstract][Full Text] [Related]
15. Ruthenium metallodendrimer against triple-negative breast cancer in mice.
Michlewska S; Wójkowska D; Watala C; Skiba E; Ortega P; de la Mata FJ; Bryszewska M; Ionov M
Nanomedicine; 2023 Sep; 53():102703. PubMed ID: 37591367
[TBL] [Abstract][Full Text] [Related]
16. Nitro-fatty acid inhibition of triple-negative breast cancer cell viability, migration, invasion, and tumor growth.
Woodcock CC; Huang Y; Woodcock SR; Salvatore SR; Singh B; Golin-Bisello F; Davidson NE; Neumann CA; Freeman BA; Wendell SG
J Biol Chem; 2018 Jan; 293(4):1120-1137. PubMed ID: 29158255
[TBL] [Abstract][Full Text] [Related]
17. Rationally Designed Ruthenium Complexes for Breast Cancer Therapy.
Golbaghi G; Castonguay A
Molecules; 2020 Jan; 25(2):. PubMed ID: 31936496
[TBL] [Abstract][Full Text] [Related]
18. BRCA Mutational Status is a Promising Predictive Biomarker for Platinum- based Chemotherapy in Triple-Negative Breast Cancer.
Tazzite A; Jouhadi H; Benider A; Nadifi S
Curr Drug Targets; 2020; 21(10):962-973. PubMed ID: 32013831
[TBL] [Abstract][Full Text] [Related]
19. Cationic liposomes as efficient nanocarriers for the drug delivery of an anticancer cholesterol-based ruthenium complex.
Vitiello G; Luchini A; D'Errico G; Santamaria R; Capuozzo A; Irace C; Montesarchio D; Paduano L
J Mater Chem B; 2015 Apr; 3(15):3011-3023. PubMed ID: 32262501
[TBL] [Abstract][Full Text] [Related]
20. Teriflunomide, an immunomodulatory drug, exerts anticancer activity in triple negative breast cancer cells.
Huang O; Zhang W; Zhi Q; Xue X; Liu H; Shen D; Geng M; Xie Z; Jiang M
Exp Biol Med (Maywood); 2015 Apr; 240(4):426-37. PubMed ID: 25304315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
